Your browser doesn't support javascript.
loading
A mutant fibrinogen that is unable to form fibrin can improve renal phenotype in mice with sickle cell anemia.
Narciso, Marilou G; Hoeting, Blair; James, Jeanne M; VandenHeuvel, Katherine; Nasimuzzaman, Md.
Afiliación
  • Narciso MG; Division of Experimental Hematology and Cancer Biology Cincinnati Children's Hospital Medical Center Cincinnati Ohio USA.
  • Hoeting B; Division of Experimental Hematology and Cancer Biology Cincinnati Children's Hospital Medical Center Cincinnati Ohio USA.
  • James JM; Division Pediatric Cardiology Medical College of Wisconsin Milwaukee Wisconsin USA.
  • VandenHeuvel K; Pathology Core Cincinnati Children's Hospital Medical Center Cincinnati Ohio USA.
  • Nasimuzzaman M; University of Cincinnati College of Medicine Cincinnati Ohio USA.
EJHaem ; 2(3): 462-465, 2021 Aug.
Article en En | MEDLINE | ID: mdl-35844706
ABSTRACT
Sickle cell anemia (SCA) causes nephropathy which may progress to kidney failure. To determine if soluble fibrinogen (FibAEK) can prevent kidney damage in mice with SCA, we performed bone marrow transplantation (BMT) of Berkeley sickle mice into wild-type fibrinogen (FibWT), and FibAEK mice that bear a germ-line mutation in fibrinogen Aα chain at thrombin cleavage site which prevents fibrin formation. We found improved albuminuria in SS FibAEK mice compared with SS FibWT mice at 12 months post-BMT due to the reduced kidney fibrosis, ischemic lesions, and increased survival of podocytes in the glomeruli, but did not improve urine concentrating defect. Therefore, our study clarifies the distinct role of fibrinogen and fibrin in the renal pathology of SCA.
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Idioma: En Revista: EJHaem Año: 2021 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Idioma: En Revista: EJHaem Año: 2021 Tipo del documento: Article